PZH2113

Part A1/A2 Primary Objective: To evaluate the safety and tolerability of PZH2113 capsules in patients with recurrent/r B-NHL predominantly composed of DLBCL, and to determine the mean toxicity (MTD) or mean toxicity (MAD) and recurrent disease (RD). Secondary Objective: To evaluate changes in pharmacokinetic (PK) characteristics and PD indices after single and multiple oral administrations of PZH2113 capsules, the effect of plasma drug concentration on the QT/QTc interval, and preliminary antitumor efficacy. Exploratory Objective: To explore possible metabolites and metabolic pathways after oral administration. Part B Primary Objective: To evaluate the preliminary antitumor efficacy of PZH2113 capsules in patients with recurrent/r B-NHL predominantly composed of DLBCL at MYD88MT. Secondary Objective: To evaluate the safety of PZH2113 capsules in patients with recurrent/r B-NHL predominantly composed of DLBCL at MYD88MT, changes in PK characteristics and PD indices after multiple oral administrations, other antitumor efficacy, and the effect of food on PK in patients with recurrent/r B-NHL predominantly composed of DLBCL at MYD88MT.